The Regulation Network of Glycerolipid Metabolism as Coregulators of Immunotherapy-Related Myocarditis
Cardiovascular Therapeutics · 2023
DOI: 10.1155/2023/8774971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2023. Verfasst von Xiguang Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Guigang City People's Hospital, Guigang, Guangxi 537100, China. Hauptthemen laut MEDLINE: Myocarditis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Medical Research Foundation, Guangdong Second Provincial General Hospital, Guangzhou Science and Technology Program key projects.
Abstract (Originalsprache)
Background
To date, immunotherapy for patients with malignant tumors has shown a significant association with myocarditis. However, the mechanism of metabolic reprogramming changes for immunotherapy-related cardiotoxicity is still not well understood.
Methods
The CD45+ single-cell RNA sequencing (scRNA-seq) of the Pdcd1-/-Ctla4+/- and wild-type mouse heart in GSE213486 was downloaded to demonstrate the heterogeneity of immunocyte atlas in immunotherapy-related myocarditis. The liquid chromatography–tandem mass spectrometry (LC-MS/MS) spectrum metabolomics analysis detects the metabolic network differences. The drug prediction, organelle level interaction, mitochondrial level regulatory network, and phosphorylation site prediction for key regulators have also been screened via multibioinformatics analysis methods.
Results
The scRNA analysis shows that the T cell is the main regulatory cell subpopulation in the pathological progress of immunotherapy-related myocarditis. Mitochondrial regulation pathway significantly participated in pseudotime trajectory- (PTT-) related differential expressed genes (DEGs) in the T cell subpopulation. Additionally, both the gene set enrichment analysis (GSEA) of PTT-related DEGs and LC-MS/MS metabolomics analysis showed that mitochondrial-regulated glycerolipid metabolism plays a central role in metabolic reprogramming changes for immunotherapy-related cardiotoxicity. Finally, the hub-regulated protease of diacylglycerol kinase zeta (Dgkz) was significantly identified and widely played various roles in glycerolipid metabolism, oxidative phosphorylation, and lipid kinase activation.
Conclusion
Mitochondrial-regulated glycerolipid metabolism, especially the DGKZ protein, plays a key role in the metabolic reprogramming of immunotherapy-related myocarditis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Guigang City People's Hospital, Guigang, Guangxi 537100, China.
- Department of General Surgery, Guangdong Provincial Second People's Hospital, Guangzhou, Guangdong 510317, China.
ORCID-Profile: Xiguang Yang, Ke He, Guoan Xiang
Förderung
- Guangdong Medical Research Foundation
- Guangdong Second Provincial General Hospital
- Guangzhou Science and Technology Program key projects
Zitieren
APA
Yang, X., Duan, X., Xia, Z., Huang, R., He, K., & Xiang, G. (2023). The Regulation Network of Glycerolipid Metabolism as Coregulators of Immunotherapy-Related Myocarditis. Cardiovascular Therapeutics. https://doi.org/10.1155/2023/8774971
Vancouver
Yang X, Duan X, Xia Z, Huang R, He K, Xiang G. The Regulation Network of Glycerolipid Metabolism as Coregulators of Immunotherapy-Related Myocarditis. Cardiovascular Therapeutics. 2023. doi:10.1155/2023/8774971
BibTeX
@article{Yang2023,
author = {Yang, Xiguang and Duan, Xiaopeng and Xia, Zhenglin and Huang, Rui and He, Ke and Xiang, Guoan},
title = {The Regulation Network of Glycerolipid Metabolism as Coregulators of Immunotherapy-Related Myocarditis},
journal = {Cardiovascular Therapeutics},
year = {2023},
doi = {10.1155/2023/8774971}
}
EUVIMED